List of Figures

Figure 1: Diagrammatic representation of JAK2 signaling in hematological malignancies
Figure 2: Signaling Pathways Involved in the Pathogenesis of Myeloproliferative Neoplasms (MPNs)
Figure 3: Diagrammatic Representation of Treatment Options for Patients With Myelofibrosis
Figure 4: Total Prevalent Population of Myelofibrosis in the 7MM (2019–2032)
Figure 5: Total Prevalent Population of Myelofibrosis in the US (2019–2032)
Figure 6: Total Diagnosed Prevalent Cases of Myelofibrosis in the US (2019–2032)
Figure 7: Type-specific Cases of Myelofibrosis in the US (2019–2032)
Figure 8: Myelofibrosis cases Based on Risk Stratification in the US (2019–2032)
Figure 9: Age-specific Cases of Myelofibrosis in the US (2019–2032)
Figure 10: Myelofibrosis Cases Based on Molecular Alterations in the US (2019–2032)
Figure 11: Treatment Eligible Pool of Myelofibrosis in the US (2019–2032)
Figure 12: Transplant Eligible/Ineligible Pool of Myelofibrosis in the US (2019–2032)
Figure 13: Total Prevalent Population of Myelofibrosis in the EU-5 (2019–2032)
Figure 14: Total Diagnosed Prevalent Cases of Myelofibrosis in the EU-5 (2019–2032)
Figure 15: Type-specific Cases of Myelofibrosis in the EU-5 (2019–2032)
Figure 16: Myelofibrosis cases Based on Risk Stratification in the EU-5 (2019–2032)
Figure 17: Age-specific Cases of Myelofibrosis in the EU-5 (2019–2032)
Figure 18: Myelofibrosis Cases Based on Molecular Alterations in the EU-5 (2019–2032)
Figure 19: Treatment Eligible Pool of Myelofibrosis in the EU-5 (2019–2032)
Figure 20: Treatment Eligible/Ineligible Pool of Myelofibrosis in the EU-5 (2019–2032)
Figure 21: Total Prevalent Population of Myelofibrosis in Japan (2019–2032)
Figure 22: Total Diagnosed Prevalent Cases of Myelofibrosis in Japan (2019–2032)
Figure 23: Type-specific Cases of Myelofibrosis in Japan (2019–2032)
Figure 24: Myelofibrosis cases Based on Risk Stratification in Japan (2019–2032)
Figure 25: Age-specific Cases of Myelofibrosis in Japan (2019–2032)
Figure 26: Myelofibrosis Cases Based on Molecular Alterations in the Japan (2019–2032)
Figure 27: Treatment Eligible Pool of Myelofibrosis in Japan (2019–2032)
Figure 28: Transplant Eligible/Ineligible Pool of Myelofibrosis in Japan (2019–2032)
Figure 29: Market Size of Myelofibrosis in the 7MM, USD million (2019–2032)
Figure 30: Market Size of Myelofibrosis in the US, USD millions (2019–2032)
Figure 31: Market Size of Myelofibrosis by Therapies in the US, USD million (2019–2032)
Figure 32: Market Size of Myelofibrosis in the EU-5, in USD million (2019–2032)
Figure 33: Market Size of Myelofibrosis by Therapies in the EU-5, USD million (2019–2032)
Figure 34: Market Size of Myelofibrosis in Japan, USD millions (2019–2032)
Figure 35: Market Size of Myelofibrosis by Therapies in Japan, USD million (2019–2032)

List of Tables

Table 1: Summary of Myelofibrosis Market, and Epidemiology (2019–2032)
Table 2: Key events
Table 3: List of the Available Risk Score for Myelofibrosis and Their Prognostic Relevance
Table 4: Mutation and karyotype-enhanced IPSS (MIPSS-70+ VERSION 2.0) for patients with primary myelofibrosis
Table 5: Total Prevalent Population of Myelofibrosis in the 7MM (2019–2032)
Table 6: Total Prevalent Population of Myelofibrosis in the US (2019–2032)
Table 7: Total Diagnosed Prevalent Cases of Myelofibrosis in the US (2019–2032)
Table 8: Type-specific Cases of Myelofibrosis in the US (2019–2032)
Table 9: Myelofibrosis Cases Based on Risk Stratification in the US (2019 –2032)
Table 10: Age-specific Cases of Myelofibrosis in the US (2019–2032)
Table 11: Myelofibrosis Cases Based on Molecular Alterations in the US (2019–2032)
Table 12: Treatment Eligible Pool of Myelofibrosis in the US (2019–2032)
Table 13: Transplant Eligible Pool of Myelofibrosis in the US (2019–2032)
Table 14: Total Prevalent Population of Myelofibrosis in the EU-5 (2019–2032)
Table 15: Total Diagnosed Prevalent Cases of Myelofibrosis in the EU-5 (2019–2032)
Table 16: Type-specific Cases of Myelofibrosis in the EU-5 (2019–2032)
Table 17: Myelofibrosis cases Based on Risk Stratification in the EU-5 (2019–2032)
Table 18: Age-specific Cases of Myelofibrosis in the EU-5 (2019–2032)
Table 19: Myelofibrosis Cases Based on Molecular Alterations in the EU-5 (2019–2032)
Table 20: Treatment Eligible Pool of Myelofibrosis cases in the EU-5 (2019–2032)
Table 21: Treatment Eligible/Ineligible Pool of Myelofibrosis in the EU-5 (2019–2032)
Table 22: Total Prevalent Population of Myelofibrosis in Japan (2019–2032)
Table 23: Total Diagnosed Prevalent Cases of Myelofibrosis in Japan (2019–2032)
Table 24: Type-specific Cases of Myelofibrosis in Japan (2019–2032)
Table 25: Myelofibrosis Cases Based on Risk Stratification in Japan (2019 –2032)
Table 26: Age-specific Cases of Myelofibrosis in Japan (2019–2032)
Table 27: Myelofibrosis Cases Based on Molecular Alterations in the Japan (2019–2032)
Table 28: Treatment Eligible Pool of Myelofibrosis in Japan (2019–2032)
Table 29: Transplant Eligible Pool of Myelofibrosis in Japan (2019–2032)
Table 30: Comparison of marketed drugs
Table 31: Jakafi, Clinical Trial Description, 2022
Table 32: INREBIC, Clinical Trial Description, 2022
Table 33: VONJO, Clinical Trial Description, 2022
Table 34: Comparison of emerging drugs
Table 35: Imetelstat, Clinical Trial Description, 2022
Table 36: Navitoclax, Clinical Trial Description, 2022
Table 37: Momelotinib, Clinical Trial Description, 2022
Table 38: GB2064, Clinical Trial Description, 2022
Table 39: 9-ING-41, Clinical Trial Description, 2022
Table 40: Navtemadlin, Clinical Trial Description, 2022
Table 41: TL-895, Clinical Trial Description, 2022
Table 42: Tagraxofusp, Clinical Trial Description, 2022
Table 43: Smac Mimetic LCL161, Clinical Trial Description, 2022
Table 44: Ilginatinib, Clinical Trial Description, 2022
Table 45: Selinexor, Clinical Trial Description, 2022
Table 46: Itacitinib, Clinical Trial Description, 2022
Table 47: Parsaclisib, Clinical Trial Description, 2022
Table 48: Luspatercept, Clinical Trial Description, 2022
Table 49: Pelabresib, Clinical Trial Description, 2022
Table 50: Bomedemstat, Clinical Trial Description, 2022
Table 51: Zinpentraxin alfa, Clinical Trial Description, 2022
Table 52: Key Market Forecast Assumptions for Imetelstat
Table 53: Key Market Forecast Assumptions for Navitoclax
Table 54: Key Market Forecast Assumptions for Momelotinib
Table 55: Key Market Forecast Assumptions for Parsaclisib
Table 56: Key Market Forecast Assumptions for Luspatercept-aamt (ACE-536)
Table 57: Key Market Forecast Assumptions for Pelabresib (CPI-0610)
Table 58: Key Market Forecast Assumptions for Bomedemstat (IMG-7289)
Table 59: Key Market Forecast Assumptions for Zinpentraxin alfa
Table 60: Key Market Forecast Assumptions for Navtemadlin
Table 61: Key Market Forecast Assumptions for Selinexor
Table 62: Market Size of Myelofibrosis in the 7MM, USD million (2019–2032)
Table 63: Market Size of Myelofibrosis in the US, USD million (2019–2032)
Table 64: Market Size of Myelofibrosis by Therapies in the US, in USD million (2019–2032)
Table 65: Market Size of Myelofibrosis in the EU-5, in USD million (2019–2032)
Table 66: Market Size of Myelofibrosis by Therapies in Germany, in USD million (2019–2032)
Table 67: Market Size of Myelofibrosis by Therapies in France, in USD million (2019–2032)
Table 68: Market Size of Myelofibrosis by Therapies in Italy, in USD million (2019–2032)
Table 69: Market Size of Myelofibrosis by Therapies in Spain, in USD million (2019–2032)
Table 70: Market Size of Myelofibrosis by Therapies in the UK, in USD million (2019–2032)
Table 71: Market Size of Myelofibrosis by Therapies in the EU-5, in USD million (2019–2032)
Table 72: Market Size of Myelofibrosis in Japan, USD million (2019–2032)
Table 73: Market Size of Myelofibrosis by Therapies in Japan, in USD million (2019–2032)